Journal of Clinical Trials
Open Access
ISSN: 2167-0870
ISSN: 2167-0870
Nagi Kumar
Departments of Epidemiology, University of South Florida College of Medicine, Tampa, Florida, USA
Dr. Nagi B. Kumar is Professor of Department of Epidemiology H. Lee Moffitt Cancer Center & Research Institute at the Universityof South Florida College of Medicine. She has completed her MA ,PhD from University of South Florida, Tampa, Florida. Dr. Nagi B. Kumar research interests include Cancer Clinical Trials, preclinical and early phase I-II clinical trials with purified isoflavones, curcuminoid complex, green tea catechins, n-3 fatty acids, tannic acid and lycopene.
Dr. Kumar focuses her research on examining the role of botanicals and biologics in the prevention, treatment and survival from cancer. Using a systematic, science-based approach, and working with a multidisciplinary team, Dr. Kumar has initiated and completed several preclinical and early phase I-II clinical trials with purified isoflavones, curcuminoid complex, green tea catechins, n-3 fatty acids, tannic acid and lycopene, laying the foundation to develop a program to accelerate agent development and validation at Moffitt Cancer Center. Funded by the National Institute of Health, the Program currently has two active phase II clinical trials evaluating the safety and effectiveness of polyphenon E and in preventing progression of prostate cancer, This year, funding was received from Novartis pharma to evaluate the safety and effectiveness of a novel agent BYM338X2202 in preventing progression of cancer cachexia. Additionally, a grant was received from Indo-US S&T Forum (IUSSTF) to conduct an Indo-US Bilateral Workshop on Accelerating Botanicals and Biologics Agent Development Research for Cancer Chemoprevention, Treatment and Survival.